ReviewVaccines2026
Challenges, Advances, and Future Directions in Nipah Virus Vaccine Development.
Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic pathogen. Since its discovery in 1998, recurrent epidemics have occurred in South and Southeast Asia, with a case fatality rate ranging from 40% to 100%. The outbreak in West Bengal, India in early 2026 has once again highlighted its severe threat to public health. To date, no licensed human vaccines or specific therapeutics against NiV are available worldwide. This review systematically summarizes the breakthroughs in antigen design for NiV vaccines, with a focus on conformational stabilization of prefusion F (pre-F) protein, chimeric G/F antigens, and multivalent nanoparticle strategies. In addition, we comparatively analyze the clinical progress of mainstream vaccine platforms, including viral vectors, mRNA and subunit vaccines. Given the sporadic nature and high mortality of NiV infection, the conventional licensing pathway relying on large-scale phase III clinical trials faces substantial practical obstacles. Accordingly, this article discusses adaptive adjustments in regulatory science. We propose several strategies to accelerate the clinical translation and emergency stockpiling of NiV vaccine candidates, including establishing unified correlates of protection thresholds, coordinating multinational regulatory resources, and optimizing the implementation of Animal Rule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.